Results of BIA survey UK R&D incentives for orphan medicines in no-deal Brexit November 2018

Guide to the Government for BIA members

This is a briefing for BIA members on the new Government and key ministerial appointments for our sector.

BIA submission to Wellcome consultation on oversight of emerging science and technology

The BIA has responded to Wellcome’s consultation on the oversight of emerging science and technology.

Shaping the future

BIA response to DIT consultation on future FTAs

The BIA has responded to the Department for International Trade (DIT)’s consultation on future Free Trade Agreements (FTAs).

BIA's Statement of Ground for intervening in Actavis vs ICOS

On 4 October 2018, the BIA submitted an application for permission to intervene in the UK Supreme Court's review of Actavis Group PTC EHF vs ICOS Corporation. This document is the Statement of Grounds for the application. 

ABPI BIA responses MHRA consultation EU Exit no deal contingency legislation

The ABPI and BIA have worked together to develop this joint submission to the MHRA consultation. We have provided our members’ views on how the MHRA’s legislation and regulatory processes would have to be modified in the event of the UK not securing a deal with the EU after the UK’s exit, with no Implementation Period. This consultation covers no-deal proposals on medicines, clinical trials and medical devices.

The BIA Guide to R&D Tax Credits For SMEs

Genomics Explained

Genomics Explained: A guide to genomics and UK excellence in the field

Antimicrobial Resistance Explained

Antimicrobial Resistance Explained: A guide to antimicrobial resistance and how UK excellence is helping tackle this global challenge